Navigation Links
Prostate cancer signal reawakens 'sleeper agent' cells in bones
Date:1/29/2014

Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.

Metastasis is the spread of cancer from one organ to another and is a highly complex process, involving cancer cells breaking away from a primary tumour, travelling to a distant organ and colonising it. Cancer cells that fail to form a tumour in the newly-encountered tissue can fall into a dormant state.

Researchers from the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in California found that dormant prostate cancer cells within bone tissue can be reawakened to a cancerous state when exposed to RANKL, a molecule commonly produced in inflammatory cells. This reawakening can lead to metastatic prostate cancer in bone tissue.

Produced by prostate cancer cells, RANKL is a signalling molecule that has been previously linked with human prostate cancer survival. In this study, researchers engineered a clinically relevant prostate cancer cell line to overproduce RANKL. They found that these cells could significantly alter the gene expression of surrounding cells in vitro, causing them to transform into aggressive cancer cells.

Researchers then injected engineered RANKL cells directly into the blood circulation of mice, which caused dormant cells within the skeleton to re-awaken, ultimately creating tumours within the bone. When the RANKL receptor was blocked, these tumours did not form.

After examination, these tumours were found to contain both the RANKL-overproducing prostate cancer cells, as well as the dormant cells, which had been transformed to become cancerous. Remarkably, the transformed cells displayed aggressive traits that would make them resistant to the normal hormone therapies used to treat prostate cancer.

The findings are preliminary as the study used prostate cancer cells that had been engineered to overproduce RANKL. The next step is to see if other cells known to produce RANKL may also be able to recruit dormant cells to colonise bone tissue.

"We are currently embarking into clinical research with human patients," said lead researcher and postdoctoral fellow Chia-Yi (Gina) Chu, PhD. "Though more work must be done to understand how RANKL reprograms dormant cells to become cancerous, we look forward to examining its influence on promoting metastasis and secondary tumours."

Each year, a quarter of a million men die from prostate cancer worldwide (1). Bones are the most common site of prostate cancer metastases and are typically lethal in 72 percent of cases based on a five year survival rate (2). "If we can prevent prostate cancer metastasis to bone we would significantly enhance patient quality of life and increase survival rates," added Chu.


'/>"/>

Contact: Omar Jamshed
omar.jamshed@bioscientifica.com
44-014-546-42206
BioScientifica Limited
Source:Eurekalert

Related medicine news :

1. Scientists develop powerful new animal model for metastatic prostate cancer
2. Researchers identify possible explanation for link between exercise & improved prostate cancer outcomes
3. Melatonin may lower prostate cancer risk
4. Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
5. Increased risk of prostate cancer in African-American men; implications for PSA screening
6. Cleveland Clinic receives grant to study role of DNA damage in treatment-resistant prostate cancer
7. Prosvent Emerges As Preferred Treatment For Enlarged Prostate
8. Pain drugs used in prostate gland removal linked to cancer outcome, Mayo Clinic-led study finds
9. Better guidelines, coordination needed for prostate cancer specialists
10. New Treatment Now Available That Extends Life in Men with Highly Advanced Prostate Cancer
11. Inflammation in prostate may reduce cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... , ... MelaKids, a Laredo-based company, has introduced a new concept for children’s ... gives us a full supply of melanin – in the back of the eye ... pigment; however, around the age of thirty, we develop a yellow-brown pigment in the ...
(Date:9/19/2017)... , ... September 19, 2017 , ... The Workgroup ... of health IT to create efficiencies in healthcare information exchange and a trusted advisor ... of their latest industry white paper, entitled Barriers to Adoption of the ERA ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), an ... orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with ... magnesium, a critical property for bone health and development. , “We’re excited to ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team Decades, ... of making a distinct rather than generic impression in the job market if one ... a stack of resumes knows that the first impression they give off is not ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology: